This strategy was deployed in both the TyU19 and YTS109 products for autoimmune disease, in which healthy donor PBMC were edited to knock out HLA-A, HLA-B and CIITA, which are required for HLA-II expression [18,19]. Here, CIITA is linked to autoimmune disease.